Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
121.80
-1.73 (-1.40%)
At close: May 5, 2025, 4:00 PM
122.15
+0.35 (0.29%)
Pre-market: May 6, 2025, 4:01 AM EDT
Biogen Revenue
Biogen had revenue of $2.43B in the quarter ending March 31, 2025, with 6.13% growth. This brings the company's revenue in the last twelve months to $9.82B, up 1.59% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$9.82B
Revenue Growth
+1.59%
P/S Ratio
1.81
Revenue / Employee
n/a
Employees
n/a
Market Cap
17.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Thermo Fisher Scientific | 42.90B |
BIIB News
- 4 days ago - Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Biogen beats quarterly profit estimates on strong demand for rare disease drugs - Reuters
- 10 days ago - Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent? - Seeking Alpha
- 20 days ago - Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union - GlobeNewsWire
- 20 days ago - EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease - Reuters
- 27 days ago - Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag - Seeking Alpha
- 4 weeks ago - Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease - GlobeNewsWire
- 5 weeks ago - Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector. - Market Watch